742144
Last Update Posted: 2017-11-17
Recruiting has ended
All Genders accepted | 20 Years-79 Years |
6 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients. subject will receive ofatumumab 8 weekly infusions.
Eligibility
Relevant conditions:
Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov